skip to Main Content

Dr. O’Reilly on the Role of Germline Testing in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Eileen O’Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses germline testing in pancreatic cancer.

Germline testing should be done in all newly diagnosed patients with pancreatic cancer, recommends O’Reilly. There is about a 10% chance that a pathogenic germline mutation will be found that is significant to the patient or family, adds O’Reilly. This can lead to cascade testing family members who may be at risk for pancreatic cancer or other malignancies as well as identify a familial genetic syndrome. Watch here . . . 

Back To Top